125 related articles for article (PubMed ID: 2746758)
1. Immunochemotherapy for murine bladder tumor with a new human recombinant tumor necrosis factor (rTNF-S), VP-16 and hyperthermia.
Iizumi T; Yazaki T; Waku M; Soma G
J Urol; 1989 Aug; 142(2 Pt 1):386-9. PubMed ID: 2746758
[TBL] [Abstract][Full Text] [Related]
2. A combined therapy of hyperthermia and tumor necrosis factor for nude mice bearing KK-47 bladder cancer.
Amano T; Kumini K; Nakashima K; Uchibayashi T; Hisazumi H
J Urol; 1990 Aug; 144(2 Pt 1):370-4. PubMed ID: 2374209
[TBL] [Abstract][Full Text] [Related]
3. Concomitant treatment of MBT-2 bladder tumour by tumour necrosis factor alpha and interferon alpha in conjunction with delayed type hypersensitivity immunotherapy.
Kadhim SA; Chin JL
Urol Res; 1991; 19(1):57-62. PubMed ID: 1674182
[TBL] [Abstract][Full Text] [Related]
4. Experimental intravesical therapy for superficial transitional cell carcinoma in a rat bladder tumor model.
Steinberg GD; Brendler CB; Squire RA; Isaacs JT
J Urol; 1991 Mar; 145(3):647-53. PubMed ID: 1997724
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor enhances the in vitro and in vivo efficacy of chemotherapeutic drugs targeted at DNA topoisomerase II in the treatment of murine bladder cancer.
Alexander RB; Isaacs JT; Coffey DS
J Urol; 1987 Aug; 138(2):427-9. PubMed ID: 3037127
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor effect of tumor necrosis factor and its induction of tumor variant of MBT-2 transitional cell carcinoma of the bladder.
Kadhim SA; Chin JL
J Urol; 1988 May; 139(5):1091-4. PubMed ID: 3361654
[TBL] [Abstract][Full Text] [Related]
7. [Combined effect of TNF and anticancer chemotherapeutic agents on murine bladder tumor (MBT-2)].
Ikemoto S; Iimori H; Nishimoto K; Hayahara N; Kamizuru M; Wada S; Hayahara M
Hinyokika Kiyo; 1992 Mar; 38(3):285-9. PubMed ID: 1523983
[TBL] [Abstract][Full Text] [Related]
8. Influence of intravesical administration of tumor necrosis factor alpha and systemic gamma-interferon on murine bladder cancer: lack of dose response.
Lee K; O'Donnell RW; Cockett AT
Urol Res; 1990; 18(4):287-9. PubMed ID: 2120837
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer.
Yu DS; Lee CF; Hsieh DS; Chang SY
Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475
[TBL] [Abstract][Full Text] [Related]
10. Enhanced anti-tumor effects of recombinant human tumor necrosis factor plus VP-16 on metastatic renal cell carcinoma in a xenograft model.
Burgers JK; Marshall FF; Isaacs JT
J Urol; 1989 Jul; 142(1):160-4. PubMed ID: 2733097
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of a novel chimera tumor necrosis factor (TNF-STH) constructed by connecting rTNF-S with thymosin beta 4 against murine syngeneic tumors.
Noguchi K; Inagawa H; Tsuji Y; Morikawa A; Mizuno D; Soma G
J Immunother (1991); 1991 Apr; 10(2):105-11. PubMed ID: 2043590
[TBL] [Abstract][Full Text] [Related]
12. Immunochemotherapy of bladder carcinoma with glucan and cyclophosphamide.
Thompson IM; Spence CR; Lamm DL; DiLuzio NR
Am J Med Sci; 1987 Nov; 294(5):294-300. PubMed ID: 3425579
[TBL] [Abstract][Full Text] [Related]
13. [Antitumor effect of combined use of purified human natural tumor necrosis factor (N-TNF) and cis-diamminedichoroplatinum (II) (cisplatin) on the implanted bladder carcinoma (MBT-2) in mice].
Sasaki A; Ohtani M; Miyanaga N; Zhongtao H; Akaza H; Koiso K; Noguchi R; Takanashi R
Nihon Hinyokika Gakkai Zasshi; 1992 Oct; 83(10):1696-702. PubMed ID: 1434274
[TBL] [Abstract][Full Text] [Related]
14. Intravesical RTNF therapy of superficial bladder cancer. A phase I study of recombinant tumor necrosis factor administered intravesically to patients with superficial bladder cancer.
Grampsas SA; Kahn K; Crawford ED
Online J Curr Clin Trials; 1994 Mar; Doc No 117():[4845 words; 36 paragraphs]. PubMed ID: 8136939
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine.
Lee CF; Chang SY; Hsieh DS; Yu DS
J Urol; 2004 Mar; 171(3):1343-7. PubMed ID: 14767345
[TBL] [Abstract][Full Text] [Related]
16. The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity.
Havell EA; Fiers W; North RJ
J Exp Med; 1988 Mar; 167(3):1067-85. PubMed ID: 3351434
[TBL] [Abstract][Full Text] [Related]
17. Modulating the antitumor immunity of MBT-2 murine bladder tumor bearing mice by postoperative administration of interferon-alpha.
Tzai TS; Shiau AL; Wu CL; Chow NH; Tsai YS
Anticancer Res; 1998; 18(5A):3355-61. PubMed ID: 9858908
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity.
Manda T; Shimomura K; Mukumoto S; Kobayashi K; Mizota T; Hirai O; Matsumoto S; Oku T; Nishigaki F; Mori J
Cancer Res; 1987 Jul; 47(14):3707-11. PubMed ID: 3594435
[TBL] [Abstract][Full Text] [Related]
19. Characterization of MBT-2 tumour cell "variant" resistant to tumour necrosis factor.
Kadhim SA; Wang JY; McLean B; Chin JL
Urol Res; 1991; 19(1):63-8. PubMed ID: 2028563
[TBL] [Abstract][Full Text] [Related]
20. The synergistic effect of hyperthermia and chemotherapy on murine transitional cell carcinoma.
Haas GP; Klugo RC; Hetzel FW; Barton EE; Cerny JC
J Urol; 1984 Oct; 132(4):828-33. PubMed ID: 6540817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
